The New England Journal of Medicine Apixaban for Extended Treatment of Provoked Venous Thromboembolism A Research Summary based on Piazza G et al. | 10.1056/NEJMoa2509426 | Published on August 30, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.

In patients with provoked venous thromboembolism and ongoing risk factors, extended treatment with low-dose apixaban for 12 months resulted in a lower risk of recurrent VTE than placebo, with a low risk of major bleeding. Full HI-PRO trial results and Research Summary: nej.md/4p6tIDo

Agree. Their ‘why’ is generally not aligned with what society needs.

Wishing all nurses a wonderful #InternationalNursesDay2025
✨️

I had a fantastic time at the Clinical Pharmacy Congress! It was a pleasure to reconnect with familiar faces and meet so many inspiring pharmacy professionals.

Fun (and slightly embarrassing) fact: this was actually my first time attending CPC — but it certainly won’t be my last!

Brilliant paper on why promethazine is not a good option to aid sleep, and yet prescribing of it has doubled in last 5 yrs. What about OTC sales too, and also diphenhydramine.
#anticholinergics
#falls #dementia #delirium
#ACBscore
www.cambridge.org/core/journal...

💭

Came across this which really resonated with me #leadership

Circle of appreciation: You’re doing some amazing things. Don’t forget them. Be proud of yourself.

Finally made it over here - looking forward to reconnecting with fellow pharmacy/healthcare colleagues!